RxDoctor Payments Data

Jennifer Poterbin

Family · West Nyack, NYNPI 1093192619

Payments from drug & device makers

$12,083in general payments, 2019–2025

Across 487 payments — averaging $24.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Gilead$1K
  • Madrigal Pharmaceuticals$643
  • plus $4K from 27 others

What the payments were for

  • Food & beverage$11,96899%
  • Education$1161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,083 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$21,988
Medicare patients
99
Services billed
346

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab16$511,862
LinzessLinaclotide50$53,265
RelistorMethylnaltrexone Bromide11$48,001
CreonLipase/Protease/Amylase22$41,862
Mesalamine32$35,327
TrulancePlecanatide15$18,303
Pantoprazole Sodium339$4,614
Famotidine339$4,455
Dicyclomine Hcl140$4,286
Vancomycin Hcl17$1,985
Mercaptopurine11$1,552
Omeprazole146$1,291
Sucralfate18$1,239
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine32$1,183
Rabeprazole Sodium19$1,012

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$1,398$511,86216 claims
AbbVieLinzess, Creon$2,772$95,12772 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor, Trulance$1,158$66,30426 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.

Other family in West Nyack

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →